Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- 31 May 2011
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 59 (5), 856-862
- https://doi.org/10.1016/j.eururo.2011.01.038
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibBritish Journal of Cancer, 2010
- Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinibAnnals of Oncology, 2009
- Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell CarcinomaClinical Cancer Research, 2008
- Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinibInternational Journal of Urology, 2007
- Sunitinib Efficacy Against Advanced Renal Cell CarcinomaJournal of Urology, 2007
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response CriteriaJournal of Clinical Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958